Our lawyers are handling Belviq lawsuits in most 50 states. This site provides a March 2022 update in these lawsuits and discusses potential settlement amounts and jury payouts for these cases.
Our attorneys also provide you with the latest update on the settlement talks. When you have a possible Belviq cancer lawsuit, call a Belviq attorney today at 800-553-8082. May 2022 Belviq Lawsuit Update on Settlement Talks
We must have a global settlement of the Belviq lawsuits in the near future. Joint motions have already been filed in Belviq lawsuits pending in various federal districts requesting the cases to be stayed since the Belviq plaintiffs are negotiating a common settlement with defendants Eisai and Arena Pharmaceuticals. Although there is no MDL for the Belviq lawsuits, the terms of the global settlement is going to be very similar.
So when you have a possible Belviq lawsuit and you have been sitting on the sidelines, you truly want to get your claim started. Don't sit in your rights. Call a Belviq attorney today. You are able to reach us at 800-553-8082. You may also call another Belviq attorney. But you want to push the ball forward or risk missing out on a settlement. March 2022 Belviq Lawsuit Update
A federal judge in one of many first Belviq colon cancer lawsuits to be filed (Johnson v. Eisai, Inc., et al.) recently rejected an attempt by the defense to have the plaintiffs'case dismissed. The defendants had filed a motion seeking dismissal of nearly all the plaintiffs'claims in the case.
But Judge Carmen Henderson (N.D. Ohio) denied the most significant aspects of that motion. Although dismissal was granted as to the claims for design defect, and punitive damages, the plaintiffs'principal claims (including negligent failure to warn) will proceed. What is Belviq?
Belviq could be the brand term for Lorcaserin, a brand new type of hormone appetite suppressant medication developed for the treatment of obesity. It had been originally developed by Arena Pharmaceuticals and later manufactured and sold by Japanese-based pharmaceutical company Eisai.
The FDA approved Belviq in June 2012. Belviq was designed to complement a reduced-calorie diet and physical activity. It worked by suppressing one's appetite. The drug came in two forms: a 10 mg tablet to be studied twice per day and a 20 mg extended-release tablet, named Belviq XR, to be studied once a day.